Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller aims to ease Post-Surgery pain without opioid risks

NCT ID NCT06901830

Symptom relief Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests an experimental painkiller called YZJ-4729 in people experiencing moderate to severe pain after orthopedic surgery. Participants receive either YZJ-4729, morphine, or a placebo through an IV, and researchers measure pain relief over 48 hours. The goal is to see if YZJ-4729 works well and is safe compared to standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
YZJ-4729 tartrate injection
What this could lead to
If successful, YZJ-4729 could offer a new option for managing acute pain after surgery, potentially with fewer side effects than morphine.
What could go wrong
This is an early phase 2 trial with only 150 participants, so results may not apply to everyone. The drug may not work better than existing treatments or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

150 people

The number who actually took part.

Started

May 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written informed consent 2. BMI≥18.0 kg/m2 and ≤28.0 kg/m2 3. ASA I to II 4. Experiences a pain intensity rating of moderate to severe acute pain following orthopedic surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery Exclusion Criteria: 1. Opioid allergy 2. Nervous system diseases (e.g. epilepsy) 3. Psychiatric disorders (e.g. depression) 4. History of difficult airways 5. Random blood glucose ≥11.1 mmol/L 6. Subjects with systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg or systolic blood pressure \< 90 mmHg 7. Abnormal pulse oxygen saturation (SpO2 \<92 %) 8. Abnormal liver function or renal function 9. Used agents that could affect the analgesic response 10. Used agents that could affect drug metabolism 11. Has previously participated in another YZJ-4729 clinical study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pain

Contacts and locations

Locations

  • Chengdu Second People's Hospital

    Chengdu, China

  • Dalian University Affiliated Zhongshan Hospital

    Dalian, China

  • Dongguan People's Hospital

    Dongguan, China

  • Henan Provincial People's Hospital

    Zhengzhou, China

  • Jinhua Central Hospital

    Jinhua, China

  • Mianyang Central Hospital

    Mianyang, China

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, China

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Shanghai First People's Hospital

    Shanghai, China

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • Suzhou University Affiliated Second Hospital

    Suzhou, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • The First Hospital of Jilin University

    Ch’ang-ch’un, China

  • The Second Affiliated Hospital of Fujian Medical University

    Quanzhou, China

  • The Second People's Hospital of Hefei

    Hefei, China

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Third People's Hospital of Chengdu

    Chengdu, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • Zhongda Hospital Southeast University

    Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.